Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study
Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among pa...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-05, Vol.16 (5), p.e0251918-e0251918 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0251918 |
|---|---|
| container_issue | 5 |
| container_start_page | e0251918 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Lo, Chien-Hsien Wang, Yu-Hsun Tsai, Chin-Feng Chan, Kuei-Chuan Li, Li-Ching Lo, Tse-Hsien Wei, James Cheng-Chung Su, Chun-Hung |
| description | Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus.
This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables.
A total of 2499 patients with newly diagnosed systemic lupus erythematosus were identified (81% females), of whom 251 were enrolled in the new-onset arrhythmia group (mean age 50.4 years) and 251 in the non-arrhythmia group (mean age 49.1 years). There was no significantly increased risk of cardiac arrhythmia (adjusted odds ratio = 1.49, 95% confidence interval: 0.98-2.25) or ventricular arrhythmia (adjusted odds ratio = 1.02, 95% confidence interval: 0.19-5.41) between the patients with and without hydroxychloroquine treatment. In addition, there were no significant differences in the risk of arrhythmia between those receiving hydroxychloroquine treatment for |
| doi_str_mv | 10.1371/journal.pone.0251918 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2529909148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A662418898</galeid><doaj_id>oai_doaj_org_article_dc63c461ee924d8bacaeb2b973894a8a</doaj_id><sourcerecordid>A662418898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-6016d2aaf98fc72c8ae8c0b8fdee5e4d14d156c588bacb298ed27e508d955a083</originalsourceid><addsrcrecordid>eNqNk11r2zAUhs3YWLtu_2BsgsHYLpLpw3akXQxC2UehUNjXrTiW5FhBsVxJ3pofsf88uU1LMnoxbLCRn_d9rXN0iuI5wXPCFuTd2o-hBzcffG_mmFZEEP6gOCaC0VlNMXu4935UPIlxjXHFeF0_Lo5YiUmFGT4u_ixj9MpCsr5HvkXdVgd_tVWd88FfjrY3CHqNFARtQSEIodumbmMB2R4NWWb6FNFvmzoUtzGZjVXIjcMYkQkZNBtIPo7xPVqiwQ-juw6aNRDNZBoNUr5PwTsU06i3T4tHLbhonu2eJ8WPTx-_n36ZnV98Pjtdns9ULWia1ZjUmgK0grdqQRUHwxVueKuNqUypSb6rWlWcN6AaKrjRdGEqzLWoKsCcnRQvb3wH56PcVTJKWlEhsCDlRJzdENrDWg7BbiBspQcrrxd8WEkIySpnpFY1U2VNjBG01FMkmIY2YsG4KIFD9vqwSxubjdEqlyyAOzA9_NLbTq78L8kJq2sqssGbncHUExOT3NiojHPQGz9O_80IpSUraUZf_YPev7sdtYK8Adu3PueqyVQuc2JJOBcTNb-Hypee2pyPXWvz-oHg7YFg6q25SisYY5Rn377-P3vx85B9vcd2BlzqonfjdJbiIVjegCr4GINp74pMsJym5rYacpoauZuaLHux36A70e2YsL-WChcV</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2529909148</pqid></control><display><type>article</type><title>Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lo, Chien-Hsien ; Wang, Yu-Hsun ; Tsai, Chin-Feng ; Chan, Kuei-Chuan ; Li, Li-Ching ; Lo, Tse-Hsien ; Wei, James Cheng-Chung ; Su, Chun-Hung</creator><creatorcontrib>Lo, Chien-Hsien ; Wang, Yu-Hsun ; Tsai, Chin-Feng ; Chan, Kuei-Chuan ; Li, Li-Ching ; Lo, Tse-Hsien ; Wei, James Cheng-Chung ; Su, Chun-Hung</creatorcontrib><description>Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus.
This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables.
A total of 2499 patients with newly diagnosed systemic lupus erythematosus were identified (81% females), of whom 251 were enrolled in the new-onset arrhythmia group (mean age 50.4 years) and 251 in the non-arrhythmia group (mean age 49.1 years). There was no significantly increased risk of cardiac arrhythmia (adjusted odds ratio = 1.49, 95% confidence interval: 0.98-2.25) or ventricular arrhythmia (adjusted odds ratio = 1.02, 95% confidence interval: 0.19-5.41) between the patients with and without hydroxychloroquine treatment. In addition, there were no significant differences in the risk of arrhythmia between those receiving hydroxychloroquine treatment for <180 days or ≥180 days, with a drug adherence rate of <50% or ≥50%, and receiving a daily dose of <400 mg or ≥400 mg.
In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0251918</identifier><identifier>PMID: 34015030</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Alcoholism ; Antimalarial agents ; Arrhythmia ; Arthritis ; Autoimmune diseases ; Biology and Life Sciences ; Cardiac arrhythmia ; Cardiology ; Cardiovascular disease ; Cardiovascular diseases ; Chronic conditions ; Chronic obstructive pulmonary disease ; Complications and side effects ; Congestive heart failure ; Coronary artery disease ; Coronaviruses ; COVID-19 ; Diabetes mellitus ; Disease transmission ; Drug abuse ; Drug dosages ; Drug therapy ; Health insurance ; Health risks ; Heart diseases ; Heart failure ; Hospitals ; Hydroxychloroquine ; Hyperlipidemia ; Hypertension ; Immunomodulators ; Inflammatory diseases ; Internal medicine ; Kidney diseases ; Liver diseases ; Lung diseases ; Lupus ; Medical research ; Medical treatment ; Medicine ; Medicine and Health Sciences ; Obstructive lung disease ; Patients ; Population ; Population studies ; Population-based studies ; Regression analysis ; Rheumatoid arthritis ; Risk factors ; Severe acute respiratory syndrome coronavirus 2 ; Statistics ; Stroke ; Systemic lupus erythematosus</subject><ispartof>PloS one, 2021-05, Vol.16 (5), p.e0251918-e0251918</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Lo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Lo et al 2021 Lo et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-6016d2aaf98fc72c8ae8c0b8fdee5e4d14d156c588bacb298ed27e508d955a083</citedby><cites>FETCH-LOGICAL-c692t-6016d2aaf98fc72c8ae8c0b8fdee5e4d14d156c588bacb298ed27e508d955a083</cites><orcidid>0000-0003-4003-008X ; 0000-0001-5729-5928</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136629/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136629/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34015030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lo, Chien-Hsien</creatorcontrib><creatorcontrib>Wang, Yu-Hsun</creatorcontrib><creatorcontrib>Tsai, Chin-Feng</creatorcontrib><creatorcontrib>Chan, Kuei-Chuan</creatorcontrib><creatorcontrib>Li, Li-Ching</creatorcontrib><creatorcontrib>Lo, Tse-Hsien</creatorcontrib><creatorcontrib>Wei, James Cheng-Chung</creatorcontrib><creatorcontrib>Su, Chun-Hung</creatorcontrib><title>Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus.
This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables.
A total of 2499 patients with newly diagnosed systemic lupus erythematosus were identified (81% females), of whom 251 were enrolled in the new-onset arrhythmia group (mean age 50.4 years) and 251 in the non-arrhythmia group (mean age 49.1 years). There was no significantly increased risk of cardiac arrhythmia (adjusted odds ratio = 1.49, 95% confidence interval: 0.98-2.25) or ventricular arrhythmia (adjusted odds ratio = 1.02, 95% confidence interval: 0.19-5.41) between the patients with and without hydroxychloroquine treatment. In addition, there were no significant differences in the risk of arrhythmia between those receiving hydroxychloroquine treatment for <180 days or ≥180 days, with a drug adherence rate of <50% or ≥50%, and receiving a daily dose of <400 mg or ≥400 mg.
In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose.</description><subject>Alcoholism</subject><subject>Antimalarial agents</subject><subject>Arrhythmia</subject><subject>Arthritis</subject><subject>Autoimmune diseases</subject><subject>Biology and Life Sciences</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Chronic conditions</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Complications and side effects</subject><subject>Congestive heart failure</subject><subject>Coronary artery disease</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes mellitus</subject><subject>Disease transmission</subject><subject>Drug abuse</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Health insurance</subject><subject>Health risks</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Hospitals</subject><subject>Hydroxychloroquine</subject><subject>Hyperlipidemia</subject><subject>Hypertension</subject><subject>Immunomodulators</subject><subject>Inflammatory diseases</subject><subject>Internal medicine</subject><subject>Kidney diseases</subject><subject>Liver diseases</subject><subject>Lung diseases</subject><subject>Lupus</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Obstructive lung disease</subject><subject>Patients</subject><subject>Population</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Regression analysis</subject><subject>Rheumatoid arthritis</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistics</subject><subject>Stroke</subject><subject>Systemic lupus erythematosus</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11r2zAUhs3YWLtu_2BsgsHYLpLpw3akXQxC2UehUNjXrTiW5FhBsVxJ3pofsf88uU1LMnoxbLCRn_d9rXN0iuI5wXPCFuTd2o-hBzcffG_mmFZEEP6gOCaC0VlNMXu4935UPIlxjXHFeF0_Lo5YiUmFGT4u_ixj9MpCsr5HvkXdVgd_tVWd88FfjrY3CHqNFARtQSEIodumbmMB2R4NWWb6FNFvmzoUtzGZjVXIjcMYkQkZNBtIPo7xPVqiwQ-juw6aNRDNZBoNUr5PwTsU06i3T4tHLbhonu2eJ8WPTx-_n36ZnV98Pjtdns9ULWia1ZjUmgK0grdqQRUHwxVueKuNqUypSb6rWlWcN6AaKrjRdGEqzLWoKsCcnRQvb3wH56PcVTJKWlEhsCDlRJzdENrDWg7BbiBspQcrrxd8WEkIySpnpFY1U2VNjBG01FMkmIY2YsG4KIFD9vqwSxubjdEqlyyAOzA9_NLbTq78L8kJq2sqssGbncHUExOT3NiojHPQGz9O_80IpSUraUZf_YPev7sdtYK8Adu3PueqyVQuc2JJOBcTNb-Hypee2pyPXWvz-oHg7YFg6q25SisYY5Rn377-P3vx85B9vcd2BlzqonfjdJbiIVjegCr4GINp74pMsJym5rYacpoauZuaLHux36A70e2YsL-WChcV</recordid><startdate>20210520</startdate><enddate>20210520</enddate><creator>Lo, Chien-Hsien</creator><creator>Wang, Yu-Hsun</creator><creator>Tsai, Chin-Feng</creator><creator>Chan, Kuei-Chuan</creator><creator>Li, Li-Ching</creator><creator>Lo, Tse-Hsien</creator><creator>Wei, James Cheng-Chung</creator><creator>Su, Chun-Hung</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4003-008X</orcidid><orcidid>https://orcid.org/0000-0001-5729-5928</orcidid></search><sort><creationdate>20210520</creationdate><title>Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study</title><author>Lo, Chien-Hsien ; Wang, Yu-Hsun ; Tsai, Chin-Feng ; Chan, Kuei-Chuan ; Li, Li-Ching ; Lo, Tse-Hsien ; Wei, James Cheng-Chung ; Su, Chun-Hung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-6016d2aaf98fc72c8ae8c0b8fdee5e4d14d156c588bacb298ed27e508d955a083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alcoholism</topic><topic>Antimalarial agents</topic><topic>Arrhythmia</topic><topic>Arthritis</topic><topic>Autoimmune diseases</topic><topic>Biology and Life Sciences</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Chronic conditions</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Complications and side effects</topic><topic>Congestive heart failure</topic><topic>Coronary artery disease</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes mellitus</topic><topic>Disease transmission</topic><topic>Drug abuse</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Health insurance</topic><topic>Health risks</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Hospitals</topic><topic>Hydroxychloroquine</topic><topic>Hyperlipidemia</topic><topic>Hypertension</topic><topic>Immunomodulators</topic><topic>Inflammatory diseases</topic><topic>Internal medicine</topic><topic>Kidney diseases</topic><topic>Liver diseases</topic><topic>Lung diseases</topic><topic>Lupus</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Obstructive lung disease</topic><topic>Patients</topic><topic>Population</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Regression analysis</topic><topic>Rheumatoid arthritis</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistics</topic><topic>Stroke</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lo, Chien-Hsien</creatorcontrib><creatorcontrib>Wang, Yu-Hsun</creatorcontrib><creatorcontrib>Tsai, Chin-Feng</creatorcontrib><creatorcontrib>Chan, Kuei-Chuan</creatorcontrib><creatorcontrib>Li, Li-Ching</creatorcontrib><creatorcontrib>Lo, Tse-Hsien</creatorcontrib><creatorcontrib>Wei, James Cheng-Chung</creatorcontrib><creatorcontrib>Su, Chun-Hung</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lo, Chien-Hsien</au><au>Wang, Yu-Hsun</au><au>Tsai, Chin-Feng</au><au>Chan, Kuei-Chuan</au><au>Li, Li-Ching</au><au>Lo, Tse-Hsien</au><au>Wei, James Cheng-Chung</au><au>Su, Chun-Hung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-05-20</date><risdate>2021</risdate><volume>16</volume><issue>5</issue><spage>e0251918</spage><epage>e0251918</epage><pages>e0251918-e0251918</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus.
This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables.
A total of 2499 patients with newly diagnosed systemic lupus erythematosus were identified (81% females), of whom 251 were enrolled in the new-onset arrhythmia group (mean age 50.4 years) and 251 in the non-arrhythmia group (mean age 49.1 years). There was no significantly increased risk of cardiac arrhythmia (adjusted odds ratio = 1.49, 95% confidence interval: 0.98-2.25) or ventricular arrhythmia (adjusted odds ratio = 1.02, 95% confidence interval: 0.19-5.41) between the patients with and without hydroxychloroquine treatment. In addition, there were no significant differences in the risk of arrhythmia between those receiving hydroxychloroquine treatment for <180 days or ≥180 days, with a drug adherence rate of <50% or ≥50%, and receiving a daily dose of <400 mg or ≥400 mg.
In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34015030</pmid><doi>10.1371/journal.pone.0251918</doi><tpages>e0251918</tpages><orcidid>https://orcid.org/0000-0003-4003-008X</orcidid><orcidid>https://orcid.org/0000-0001-5729-5928</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-05, Vol.16 (5), p.e0251918-e0251918 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2529909148 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Alcoholism Antimalarial agents Arrhythmia Arthritis Autoimmune diseases Biology and Life Sciences Cardiac arrhythmia Cardiology Cardiovascular disease Cardiovascular diseases Chronic conditions Chronic obstructive pulmonary disease Complications and side effects Congestive heart failure Coronary artery disease Coronaviruses COVID-19 Diabetes mellitus Disease transmission Drug abuse Drug dosages Drug therapy Health insurance Health risks Heart diseases Heart failure Hospitals Hydroxychloroquine Hyperlipidemia Hypertension Immunomodulators Inflammatory diseases Internal medicine Kidney diseases Liver diseases Lung diseases Lupus Medical research Medical treatment Medicine Medicine and Health Sciences Obstructive lung disease Patients Population Population studies Population-based studies Regression analysis Rheumatoid arthritis Risk factors Severe acute respiratory syndrome coronavirus 2 Statistics Stroke Systemic lupus erythematosus |
| title | Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T11%3A46%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20hydroxychloroquine%20and%20cardiac%20arrhythmia%20in%20patients%20with%20systemic%20lupus%20erythematosus:%20A%20population-based%20case%20control%20study&rft.jtitle=PloS%20one&rft.au=Lo,%20Chien-Hsien&rft.date=2021-05-20&rft.volume=16&rft.issue=5&rft.spage=e0251918&rft.epage=e0251918&rft.pages=e0251918-e0251918&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0251918&rft_dat=%3Cgale_plos_%3EA662418898%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2529909148&rft_id=info:pmid/34015030&rft_galeid=A662418898&rft_doaj_id=oai_doaj_org_article_dc63c461ee924d8bacaeb2b973894a8a&rfr_iscdi=true |